Abstract
To develop new treatment strategies for patients with leptomeningeal metastases (LM), potential therapeutic agents have to be tested in murine models first. In vivo magnetic resonance imaging has an additive value in non-invasive monitoring of the effects of therapeutic agents on LM. Previously, we described a reproducible mouse model for B16F-10 melanoma LM. In this paper, we visualize leptomeningeal melanoma metastases in mice on both T2 weighted MR images and gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA) enhanced T1 weighted MR images, using a 4.7T MR spectrometer. We conclude that both MR sequences can be used to detect and monitor LM of melanoma cells in mice. Our data further suggest that LM are more clearly visualized using T1 weighted Gd-DTPA enhanced subtraction imaging than T2 weighted imaging.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
DeAngelis LM: Current diagnosis and treatment of leptomeningeal metastasis. J Neuro-Oncol 38: 245–252, 1998
Reijneveld JC, Taphoorn MJ, Voest EE: A simple mouse model for leptomeningeal metastases and repeated intrathecal therapy. J Neuro-Oncol 42: 137–142, 1999
Reijneveld JC, Taphoorn MJ, Kerckhaert OA, Drixler TA, Boogerd W, Voest EE: Angiostatin prolongs the survival of mice with leptomeningeal metastases. Eur J Clin Invest 33: 76–81, 2003
Nip J, Brodt P: The role of the integrin vitronectin receptor, alpha v beta 3 in melanoma metastasis. Cancer Metastasis Rev 14: 241–252, 1995
Birch M, Mitchell S, Hart IR: Isolation and characterization of human melanoma cell variants expressing high and low levels of CD44. Cancer Res 51: 6660–6667, 1991
Marshall JF, Hart IR: The role of alpha v-integrins in tumour progression and metastasis. Semin Cancer Biol 7: 129–138, 1996
Escott EJ: A variety of appearances of malignant melanoma in the head: a review. Radiographics 21: 625–639, 2001
Runge VM, Price AC, Wehr CJ, Atkinson JB, Tweedle MF: Contrast enhanced MRI. Evaluation of a canine model of osmotic blood-brain barrier disruption. Invest Radiol 20: 830–844, 1985
Schumacher M, Orszagh M: Imaging techniques in neoplastic meningiosis. J Neuro-Oncol 38: 111–120, 1998
Yousem DM, Patrone PM, Grossman RI: Leptomeningeal metastases: MR evaluation. J Comput Assist Tomogr 14: 255–261, 1990
Chamberlain MC, Sandy AD, Press GA: Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology 40: 435–438, 1990
Ushio Y, Shimizu K, Aragaki Y, Arita N, Hayakawa T, Mogami H: Alteration of blood-CSF barrier by tumor invasion into the meninges. J Neurosurg 55: 445–449, 1981
Jaeckle KA, Krol G, Posner JB: Evolution of computed tomographic abnormalities in leptomeningeal metastases. Ann Neurol 17: 85–89, 1985
Yang M, Baranov E, Jiang P, Sun FX, Li XM, Li L, et al.: Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases. Proc Natl Acad Sci USA 97: 1206–1211, 2000
Contag PR, Olomu IN, Stevenson DK, Contag CH: Bioluminescent indicators in living mammals. Nat Med 4: 245–247, 1998
Edinger M, Sweeney TJ, Tucker AA, Olomu AB, Negrin RS, Contag CH: Noninvasive assessment of tumor cell proliferation in animal models. Neoplasia 1: 303–310, 1999
Rehemtulla A, Stegman LD, Cardozo SJ, Gupta S, Hall DE, Contag CH, et al.: Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia 2: 491–495, 2000
Benveniste H, Blackband S: MR microscopy and high resolution small animal MRI: applications in neuroscience research. Prog Neurobiol 67: 393–420, 2002
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brandsma, D., Taphoorn, M.J., Reijneveld, J.C. et al. MR Imaging of Mouse Leptomeningeal Metastases. J Neurooncol 68, 123–130 (2004). https://doi.org/10.1023/B:NEON.0000027742.78828.99
Issue Date:
DOI: https://doi.org/10.1023/B:NEON.0000027742.78828.99